US2019153476A1PendingUtilityA1
Crispr-cas systems for altering expression of gene products
Est. expiryDec 12, 2032(~6.4 yrs left)· nominal 20-yr term from priority
Inventors:Feng Zhang
C12N 15/00C12N 2310/10C12N 15/111C12N 15/63C12N 9/96C12N 9/52C12N 9/22C12N 15/902A61K 38/47C12N 15/1082C12N 15/102C12N 2800/90C12N 15/85A61K 38/43C12N 2310/20A61K 38/46C12N 15/907C12Q 1/68C12N 2800/80C12N 9/14C12N 2800/30C12N 9/226
73
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.
Claims
exact text as granted — not AI-modified1 - 50 . (canceled)
51 . A method of altering expression of at least one gene product comprising:
introducing into a eukaryotic cell having a target sequence, an engineered, non-naturally occurring CRISPR-Cas system comprising:
one or more vectors comprising:
(a) at least one first nucleotide sequence encoding an RNA that hybridizes with the target sequence, and
(b) a second nucleotide sequence encoding a Cas9,
whereby the Cas9 is directed to the target sequence by the RNA and expression of the at least one gene product is altered.Join the waitlist — get patent alerts
Track US2019153476A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.